Goodwin Procter has advised Parabilis Medicines. Covington has advised the underwriters. Parabilis Medicines, Inc., a clinical-stage biopharmaceutical company, has completed an upsized initial public offering, raising...
Parabilis Medicines Completes $770 Million Upsized IPO and $75 Million Private Placement
Elevar Therapeutics’ Global Licensing Agreement with Relay Therapeutics
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Elevar Therapeutics in the transaction, and Goodwin Procter advised Relay Therapeutics. Elevar Therapeutics, Inc. (Elevar), a majority-owned subsidiary...
Jade Biosciences’ Merger with Aerovate Therapeutics
Gibson, Dunn & Crutcher advised Jade Biosciences on the transaction, and Cooley advised the placement agents; while Goodwin Procter advised Aerovate Therapeutics, Inc. Aerovate Therapeutics, Inc....
Isomorphic Labs’ Multi-Target Research Collaboration with Novartis
Goodwin advised Isomorphic Labs on its strategic research collaboration with Novartis. Isomorphic Labs has signed a strategic research collaboration with Novartis to discover small molecule therapeutics against...
Novo Nordisk’s Research Collaborations with Omega Therapeutics and Cellarity
Goodwin advised Flagship Pioneering on the matter. Hogan Lovells acted for Omega Therapeutics, Inc. Novo Nordisk, Omega Therapeutics, Inc. (Nasdaq: OMGA) and Cellarity Inc. announced that Novo Nordisk...
Rapport Therapeutics’ $150 Million Series B Funding Round
Goodwin advised Rapport Therapeutics on the fundraising. Rapport Therapeutics announced the completion of its $150 million in Series B funding. Led by Cormorant Asset Management, the...
Bicara Therapeutics’ $108 Million Series B Financing
Goodwin Procter advised Bicara Therapeutics on the deal. Bicara Therapeutics announced the completion of its oversubscribed $108 million Series B financing to advance the company’s lead program...
Rapport Therapeutics’ $100 Million Series A Financing
Goodwin Procter advised Rapport Therapeutics, Inc. on the deal. Rapport Therapeutics, Inc. announced its launch with a $100 million Series A financing from Third Rock Ventures, ARCH...
Alnylam Pharmaceuticals’ $1.035 Billion Notes Offering
Goodwin Procter advised Alnylam Pharmaceuticals, Inc. on the deal, while Davis Polk advised the representative of the initial purchasers. Alnylam Pharmaceuticals, Inc. announced its inaugural offering...